About Noxopharm
Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.
It has three active drug development programs: its clinical drug candidate Veyonda®, plus two innovative technology platforms – ChromaTM (oncology) and SofraTM (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.
Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
Veyonda® is currently not approved in Australia or any other country
